A360
Key Takeaways✦ Atlas AI
01
Novo Nordisk has launched a reformulated oral Ozempic for type 2 diabetes, replacing Rybelsus with lower-dose tablets (1.5mg, 4mg, 9mg) that maintain efficacy and safety, offering a new daily pill option.
02
This release signifies a growing trend towards oral GLP-1 medications, following other FDA approvals this year, providing more convenient and diverse treatment choices for patients managing type 2 diabetes.
03
The availability of both oral and injectable Ozempic, with a higher 25mg oral dose potentially by late 2026, expands patient accessibility and preference, potentially improving adherence and treatment outcomes for diabetes management.
Atlas AI
A reformulated oral tablet version of Ozempic is now available for adults with type 2 diabetes. This new daily pill, released by Novo Nordisk, replaces the previous Rybelsus oral medication.
The new Ozempic pill comes in 1. 5 mg, 4 mg, and 9 mg doses, which are lower than the previous Rybelsus doses.
Officials state the reformulated pill maintains the same efficacy and safety profile as the original formulation.
This release follows the FDA's approval of other GLP-1 medications in oral form this year, including an oral Wegovy for weight management. Another oral GLP-1, Foundayo, was approved with a requirement for further study on potential risks.
Novo Nordisk anticipates a decision on a 25 mg Ozempic tablet dose by late 2026. The availability of both oral and injectable forms offers additional treatment options for patients with type 2 diabetes.
